| Patient (sex/age) | Immunotherapy | Onset(after initial immunotherapy) | Treatment | Resolution period | Immunotherapy continue | Follow up |
|---|---|---|---|---|---|---|
| M/63 | Ipilimumab+pembrolizumab | 1 month | Corticosteroids | 6 weeks | Pembrolizumab only | 15 months |
| M/64 | Pembrolizumab | 13 months | Corticosteroids (1㎎/㎏/day) | 6 weeks | X | 7 months |
| M/82 | Nivolumab | 1 month | Corticosteroids (1㎎/㎏/day) | NM | X | 2 years |
| M/83 | Nivolumab | 6 weeks | Corticosteroids (1㎎/㎏/day) | NM | NM | NM |
| W/67 | Bevacizumab | 2 days | Aspirins(81㎎/day) | 3 months | NM | NM |